| 2017-06-26 |
1 |
Complaint |
“the ’999 patent”), 7,619,001 (“the ’001 patent”), 7,803,840 (“the ’840
patent”) and 8,399,514 (“the …regarding the ’376 patent, the ’999 patent, the ’001
patent, the ’840 patent and the ’514 patent, has a substantial…is an action for patent infringement of U.S. Patent Nos. 6,509,376 (“the ’376
patent”), 7,320,999 (“the…the ’514 patent”) arising under the patent laws of the United States,
Title 35, United States Code, §§ … FIRST COUNT FOR PATENT INFRINGEMENT (’376 PATENT)
23. Biogen realleges |
External link to document |
| 2018-08-31 |
166 |
Stipulation of Dismissal |
infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”),
7,320,999 (“the ʼ999 patent”) and 8,399,514…8,399,514 (“the ’514 patent”) (collectively, the “Asserted
Patents”): Biogen MA Inc. v. Impax Laboratories, …Stipulation grants no rights to Impax under any patents or other proprietary
rights.
… 26 June 2017
1:17-cv-00823
835 Patent - Abbreviated New Drug Application(ANDA)
Defendant |
External link to document |
| 2019-03-06 |
236 |
Memorandum Opinion |
alleging infringement of U.S.
Patent Nos. 6,509,376 ("the ' 376 patent"), 7,320,999 ("…x27; 514
patent") (collectively, "patents-in-suit" or "asserted patents").
…quot;the ' 999 patent"), 7,619,001 ("the ' 001
patent"), 7,803 ,840 ("the …the ' 840 patent"), 8,759,393 ("the ' 393 patent"), and 8,399,514 ("the &#…quot;It is a bedrock principle of patent law that the
claims of a patent define the invention to which the |
External link to document |
| 2019-10-11 |
315 |
Stipulation of Dismissal |
infringement of
U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ’999 patent”), and 8,399,514… alleging infringement of U.S.
Patent No. 7,619,001 (“the ’001 patent”) by submission of Hetero’s ANDA…8,399,514 (“the
’514 patent”) by submission of Hetero’s Abbreviated New Drug Application (“ANDA”) No.
210500…
Product”) prior to the expiration of the ’001 patent, i.e., June 20, 2020.
2. All claims… defenses, and counterclaims regarding the ’001 patent brought in C.A.
No. 19-211 are dismissed without |
External link to document |
| 2019-10-24 |
317 |
Stipulation |
4, 6, 8-13, 15, and 16 of U.S. Patent No. 8,399,514 (“the
’514 patent”) (collectively, the “Asserted …Asserted Claims” of the “Asserted Patent”) by submitting, or
causing to be submitted, Abbreviated New Drug Application… WHEREAS claims 5, 7, 14, and 17-20 of the ’514 patent have not been asserted;
WHEREAS, MSN’…(A)(vii)(IV) that, in its opinion, the Asserted Patent is invalid, unenforceable, or
would not be infringed…Products prior to the expiration of the Asserted Patent in accordance with the labeling
proposed in MSN |
External link to document |
| 2019-10-25 |
319 |
Stipulation |
4, 6, 8-13, 15, and 16 of U.S. Patent No. 8,399,514 (“the ’514
patent”) (collectively, the “Asserted …Asserted Claims” of the “Asserted Patent”) by submitting, or causing
to be submitted, Abbreviated New Drug Application… WHEREAS claims 5, 7, 14, and 17-20 of the ’514 patent have not been asserted;
WHEREAS, Biogen…by Sandoz of the Asserted Claims of the Asserted Patent based Sandoz’s
filing of ANDA No. 210414;
…Prinston of the Asserted
Claims of the Asserted Patent based on Prinston’s filing of ANDA No. 210512;
|
External link to document |
| 2019-11-01 |
321 |
Stipulation |
infringement of U.S. Patent Nos.
6,509,376 (“the ’376 patent”), 7,320,999 (“the ’999 patent”), 7,619,001 (“…(“the ’001 patent”)
7,803,840 (“the ’840 patent), 8,759,393 (“the ’393 patent”), and 8,399,514 (“the …the ’514 patent”) by
submission of Sawai’s Abbreviated New Drug Application (“ANDA”) No. 210285: Biogen… of claims 1-4, 6, 8-13, 15, and 16 of the ’514 patent
{01502985;v1 }
Case 1:17-cv-00823-MN Document…that claims 1-4, 6, 8-13, 15, and 16 of the ’514 patent are
invalid for failure to comply with one or |
External link to document |
